MED01 Research Brief — Historical Evidence Landscape: Medical Cannabis & Cannabinoid Research, 1960s → 2026

MED01-P1 — Foundations and Rediscovery, 1960 – 1999 (part 1 of 3)

FROZEN — DO NOT MODIFY

Version v1.0 · FROZEN 2026-09-20 — authorized by Danny after ChatGPT and Gemini editorial passes. MED01-wide evidence search cutoff: 2026-09-20. This file is never edited again. Any later clarification or correction is logged in corrections.md, and both researchers receive it identically.

Governing protocol: PROTOCOL-MEDICAL v0.5 BASELINE (git 7beaff6) · base PROTOCOL.md v1.4 Independence rule: ChatGPT and Gemini receive this brief with substantively identical instructions. Neither sees the other’s pass until both are filed (§M1 firewall). Not medical advice. This round describes a research literature. It does not evaluate any treatment for any reader.

0. How MED01 is organized (parts)

Topic chosen by Danny 2026-09-20 (roadmap item 1) as the backdrop for the whole medical corpus. Sixty years is too much for one pass, so MED01 runs in parts, by era:

• Each part has its own frozen brief, its own two independent passes, its own firewall, verification, and cross-audit. A part reaches PART LOCK (P1 LOCK, …) — passes filed, verification and ledger entries complete, interim synthesis done, cross-audit issues resolved or documented — before the next part’s brief is frozen, so each part’s lessons improve the next brief. MED01 itself stays UNLOCKED under PROTOCOL-MEDICAL §M10 until P1–P3, the final synthesis, the plain-English derivatives, and the required audits are all complete.
• One MED01-wide evidence search cutoff. It is set once, when the P1 brief freezes, and is inherited unchanged by P2 and P3, so the finished landscape describes a single evidence snapshot rather than three different “present days.”
• All parts share one ledger (MED01-C001 onward, continuous), the shared SOURCE_LIBRARY, and one final synthesis assembled after the last part. Each part also gets a short interim synthesis.
• The window boundaries are administrative, not findings. Researchers are asked (§3, F1) to say where the literature itself shows natural phase changes, with evidence. Boundary rule. Each publication belongs strictly to the part containing its publication year. A research programme that crosses a boundary may be mentioned contextually in the earlier part and flagged for continuation, but its later publications are handled in the later part. For non-publication milestones begun inside the window and resolved after it (filings, regulatory proceedings, programmes, studies completed but not yet published), report the documented state as of 1999-12-31 and tag the downstream resolution for handoff to P2 — do not narrate the resolution here.

1. Research question (P1)

Between 1960 and 1999, what was the medical and scientific research literature on cannabis and cannabinoids — who was studying what, in which populations, with which preparations and study designs, under which legal and regulatory conditions — and what did the best evidence syntheses of that period and about that period conclude?

This is an evidence map, not an efficacy review. The unit of analysis is the literature. The round’s claims are claims about what was studied, how, where, and what was concluded at the time — not verdicts on whether cannabis works for anything. Present-day efficacy questions are handed off to later condition-specific rounds.

2. Scope

• In scope: human clinical and observational research; the preclinical and chemical discoveries that redirected human research; pharmaceutical cannabinoid development and approvals; government and professional-body reports; the legal and regulatory conditions that governed research access; how harms were studied; the geography and funding of the research.
• Out of scope: any present-day verdict on efficacy or safety (→ later rounds); recreational-use epidemiology except where it was the harms literature of the period; cultivation; policy advocacy for or against legalization; anything published after 1999 as a primary source — but later histories, reviews, and bibliometric analyses about 1960–1999 are in scope and wanted.
• Populations / interventions / outcomes: not restricted — recording which ones the period studied is the point. Every study mentioned is still described to the standard in §4 rule 3 (full extraction for claim-supporting and keystone studies; a compact survey line for the rest).
• Jurisdictions: no restriction; regulatory statements must name jurisdiction and date (§M8). Do not treat the United States as the default.
• Literature window: primary sources published 1960-01-01 → 1999-12-31. Pre-1960 material only as one short background paragraph, clearly labeled.
• Evidence search cutoff date (§M12a) — MED01-wide: 2026-09-20 (the P1 freeze date). In P1 it governs only retrospective sources about the period (primary sources are bounded by the window). Both researchers search through this same date; P2 and P3 inherit it unchanged.

3. Key questions

A. Volume and shape. How much was published, and in which fields and journals? Report counts by decade or by inflection period (1960–69, 1970–79, 1980–89, 1990–99), not year-by-year tallies reconstructed from memory. Prefer published bibliometric analyses of this literature for trends, cited like any other source, alongside one reproducible database query of your own (database, exact query string, date run, result) that the verifier can re-run. Never smooth, interpolate, or estimate a count; if you cannot obtain one, say so. State what counts cannot capture (indexing gaps for older and non-English literature).

B. Discoveries that redirected the field. Which chemical, pharmacological, or biological findings in this window changed what human researchers could ask? For each: what was shown, in what system (in vitro / animal / human), and what it did not show at the time.

C. What was studied in humans. Which indications and symptoms were studied, and in roughly what order? Report only what contemporaneous sources identify as motivating, enabling, or constraining that research; where they are silent, say the reason is uncertain — do not supply a motive. For each indication: the study designs used, typical sample sizes, preparations and routes, comparators, and outcome measures of the period.

D. Preparations. Whole plant, smoked cannabis, extracts, isolated and synthetic cannabinoids: what was actually administered in the period’s studies, and how did that change? Which pharmaceutical cannabinoids were developed, and what were they approved for, where, when, on what trial evidence?

E. Study quality by the standards of the time and of today. What designs dominated? Where randomized controlled trials existed: how large, how blinded, which comparator, which design (parallel / crossover)? What would a modern appraisal flag? Do not retro-grade every study; characterize the body, and appraise the specific studies you lean on.

F. Conditions of research. F1 — natural phases: where does the literature itself show turning points, and what is the evidence for each? F2 — law and access: which legal, scheduling, supply, and funding conditions governed who could study what, by jurisdiction and date? Separate documented effects on research from asserted ones. F3 — geography and funding: where was the work done and who paid for it?

G. Harms research. How were dependence, cognition, psychiatric effects, respiratory and cardiovascular effects, reproductive effects, and drug interactions studied in this period? In which populations (patients vs. recreational users vs. volunteers)? Any statement about the balance of attention between harms and benefits must rest on a stated empirical basis — publication counts, grant or funding records, documented agency priorities — not on impression; if no such basis is available, say the balance cannot be characterized.

H. What the syntheses said. Which government commissions, professional bodies, and review articles assessed this evidence, during the period or later? Report what each concluded as that body’s conclusion, attributed and dated — never as this program’s finding.

I. Synthesis targets. (1) An era table: indication × design × preparation × approximate volume. (2) A list of areas for which no human study was identified in the documented searches, kept distinct from areas found only in non-human evidence. This is not a systematic review: “none identified” is never worded as “none exists.” (3) Open threads handed to P2. (4) End-of-era statement — “what did medicine and science actually know by the end of 1999?” Answer in three tiers, each tied to the designs that supported it: reasonably established in humans · suggested but not established (small, uncontrolled, or preclinical only) · asserted in period sources, but for which this round did not identify traceable supporting evidence (a statement about our search, not proof that none existed). This describes the state of knowledge in 1999, not today’s.

Scope guard. MED01 maps how each evidence area evolved and what level it reached. It does not perform the condition-specific review. If an indication has many studies, characterize the body (how many, what designs, what preparations, what the period’s syntheses concluded) and appraise only the few studies you lean on; the full efficacy question belongs to that indication’s own later MED round. Name each such handoff.

4. Evidence standards (PROTOCOL-MEDICAL §M3–M8 — binding)

1. Every source gets a source type and a study design (§M3): primary | sr-ma | narrative-review | guideline | official × rct | interventional-nr | observational | case | animal | in-vitro | mechanistic. For a review or report, say what designs it rests on.
2. Histories are secondary sources. A narrative history or textbook chapter can support “historian X says,” not the underlying fact. For any keystone event or study, cite the primary document as well.
3. Two tiers of study description.
   • Full extraction — population · condition · sample size · preparation and cannabinoid content · dose · route · duration · comparator · outcome · result — is mandatory for every study that supports a candidate claim (CAND-01…30) and for every keystone study in §3B and §6 Q1, Q2, Q9, Q10, Q11.
   • Survey citations — for the wider literature described in the narrative, use one compact line: [Author, Year | design | N | population / indication | preparation / route | primary outcome]. This keeps the map broad without exhausting the pass. A study promoted into a claim later gets the full extraction.
   • In both tiers write not reported or not accessible to me — never leave a field out, never guess.
4. Comparative results only. If you report that a treatment did something in a controlled study, give the comparative estimate appropriate to the design (between-group for parallel trials; between-condition for crossover trials). Change from baseline alone is labeled as such.
5. No drift (§M7, D1–D14). Animal ≠ human. Association ≠ cause. Symptom relief ≠ disease modification. A synthetic cannabinoid ≠ cannabis. One route, dose, or population ≠ all. Short-term ≠ long-term. “No harm reported” ≠ safe. A 1970s result is not evidence about today’s products.
6. Historical-claim discipline. Distinguish documented (a dated primary document shows it) from commonly stated (repeated in reviews without a traceable source). Famous anecdotes of this field are often the second kind; label them. 6a. Historical-source rule — no hindsight. Later retrospective sources (histories, modern reviews, bibliometric studies) may be used to verify chronology, source identity, and regulatory context, and to locate earlier literature. But any claim about what was known, supported, uncertain, or accepted by the end of the era must ultimately trace to evidence available during that era. Where later scholarship changed the interpretation of an older finding, report the contemporaneous state and the later reinterpretation separately, each with its own date and source. Mark every source period (published 1960–1999) or retrospective (published later).
7. Harms get the same rigor as benefits (§M4 harm domains).
8. Regulatory statements name jurisdiction and date (§M8).
9. Publication integrity: flag any source you know to be retracted, corrected, or disputed.
10. Identifiers: DOI and/or PMID for every journal source; for reports and legal documents, the issuing body, document number, year, and a stable URL. Old papers often lack DOIs — give PMID or full journal/volume/page. If you cannot verify a citation’s details, say so; do not complete it from memory.
11. No advice, no present-day efficacy verdicts.

4a. Search requirements (§M12b)

• Minimum sources to consult: PubMed/MEDLINE · Cochrane Library · ClinicalTrials.gov (the registry did not exist for most of this window — it opened to the public in 2000. Note any retrospective registrations or follow-on trials you find, but never treat the absence of a registry entry as evidence about a pre-2000 study) · government and international-body archives relevant to your jurisdictions · at least one bibliometric or historical analysis of the cannabis literature, if any exists.
• Core search concepts: cannabis · marijuana/marihuana · hashish · cannabinoid(s) · named individual cannabinoids and pharmaceutical cannabinoids of the period · therapeutic use · clinical trial · adverse effects — combined with date limits 1960–1999, plus unrestricted-date searches for histories and reviews of the period.
• Search log (required, at the end of the pass): tools and databases actually used · exact query strings · dates run · result counts where relevant · what you could not access. If you relied on training knowledge rather than a live search for any item, say which.
• This is not a systematic review and must not be described as one.

5. Required output format

1. Narrative answer to A–I, in that order, with inline citations.
2. Candidate claims — numbered CAND-01…, at most 30, each: one-sentence claim · claim type (literature-shape | discovery | clinical-finding-of-the-period | regulatory | harms-research | synthesis-conclusion | absence) · supporting source(s) with identifiers · source type × study design · population / preparation / route / comparator / outcome where the claim concerns a study · your confidence · what would change your mind.
3. Era table (I-1) and not-studied list (I-2).
4. Reference list with identifiers, and for each reference: verified live | from memory — unverified, and period | retrospective (rule 6a).
5. Self-flagged weak points: citations you are unsure of, claims resting on a single secondary source, counts you could not reproduce.
6. Search log (§4a).
7. State at the top which brief version you worked from.

6. Archive material to be tested (§M12)

Overlap check complete (2026-09-20): material overlap — archive audit required and filed (archive-audit.md; not shared with the researchers). Under the anchoring safeguard (§M12) the archive reaches you only as the questions below: neutrally worded, with no indication of what the earlier teaching said. Answer each from primary documents; several extend the key questions in §3 — answer them there and cross-reference.

Anti-weighting guard. These questions (and the public claims in §7) are audit probes — not a sampling frame and not a statement of historical importance. They over-represent some subjects and one country’s regulatory history. They must not determine the geographic or topical weighting of your A–I evidence map: build the map from the literature first, then answer the probes.

• Q1 (→B). Who first isolated, determined the structure of, and synthesized the principal psychoactive constituent of cannabis? When and where was each step published, and what prior work did it build on? Do the same for each other major plant cannabinoid characterized by 1999.
• Q2 (→B). If the window produced discoveries about how cannabinoids act in the body, give the documented sequence: investigators, institutions, year, primary publication for each step — and say exactly what kind of evidence each step was.
• Q3 (→A, F3). Which research groups, institutions, and countries produced this literature, by decade, and how concentrated was it? Use bibliometric analyses where they exist.
• Q4 (→F2). How was cannabis for research legally produced and supplied in each jurisdiction that permitted research? Who held the licences or contracts, from when, under which agency — and what did contemporaries document about how those arrangements affected which studies could be done?
• Q5 (→F2, G). What did public research funders of the period state as their cannabis research priorities? What does bibliometric or grant-level evidence show about the balance between harm-focused and therapeutic studies, by decade and country?
• Q6 (→F2, C). Was controlled clinical research with cannabis or cannabinoids in humans legally possible under national drug-control law in the period? By jurisdiction and date: what approvals were required, and which controlled human studies were actually completed (design, sponsor)?
• Q7 (→H). Which national or official commissions and expert bodies reported on cannabis in the window? For each: who commissioned it, what it concluded on health effects and therapeutic use, what it recommended, and the documented government response.
• Q8 (→H). For any official cannabis report (any era) about which suppression, confiscation, or destruction is claimed: what do primary records show about its publication, distribution, and availability? Label each account documented or commonly stated.
• Q9 (→D). For each synthetic or pharmaceutical cannabinoid that reached human testing by 1999: originator, first synthesis, first clinical studies, indication, approval dates by jurisdiction, scheduling and any rescheduling, commercial ownership.
• Q10 (→D, E). Were different preparations or routes of administration compared head-to-head for the same indication in the period? If so: designs, sample sizes, comparators, comparative results, sponsors, and where published.
• Q11 (→C). For any disease-modification claim (as distinct from symptom relief) that traces its origin to this period, what were the earliest studies — in vitro, animal, or human — with designs, models, doses, and results? What follow-up occurred through 1999, and how has later literature characterized those studies? (Report period state and later reinterpretation separately — rule 6a.)
• Q12 (→F2). What individual-patient or compassionate-access routes to cannabis existed under national governments? Legal basis, start and end dates, patient numbers at each stage, stated reasons for any closure, and any outcome data collected.
• Q13 (→F2). What formal petitions or proceedings to change the legal scheduling of cannabis occurred, 1970–1999? Petitioner, dates, findings of any administrative hearing, final decision, stated grounds. Report only what bears on research or medical access.
• Q14 (background paragraph only). Of the pre-1960 claims commonly repeated in histories of medical cannabis, which rest on a dated primary document and which are commonly stated only? One paragraph; do not expand.

7. Public claims to test (neutral wording; P1 window)

These circulate widely. They are things to test, not the skeleton of the history (see the anti-weighting guard in §6). Report what the evidence of the period shows for each — supported, partly supported, unsupported, or untraceable.

• P1. “There was almost no research on cannabis before legalization.”
• P2. “Drug scheduling made cannabis research impossible.”
• P3. “Early research looked only for harms.”
• P4. “Medical benefits were already proven decades ago and then ignored.”
• P5. “Findings about the period’s pharmaceutical cannabinoids are findings about cannabis.”
• P6. “Government-commissioned reports of the period reached conclusions that governments then disregarded.”
• P7. “A government-held patent on cannabinoids proves the government knew of medical benefits.” (Report what was filed, by whom, when, claiming what, on what experimental evidence. Filing and grant dates may straddle 1999 — report the filing here and flag the rest for P2.)

8. What “done” looks like

A reader finishes P1 knowing what the 1960–1999 literature consisted of, what it could and could not show, and which of today’s common historical claims about it are documented. The ledger holds 20–35 verified claims, most of them about the literature itself. Nothing in it reads as a statement about what cannabis does for a patient today.

9. Known limits of this round as a protocol test

An evidence map leans on reviews, reports, and histories, so it exercises citation identity and support, publication integrity, the two-axis source rules, drift checks, the historical documented-vs-stated discipline, search logs, the completeness probe, and the cross-audit. It exercises lightly the trial-level controls (RoB 2 variants, comparative-effect rule, registry cross-check) — those get their real test in P2 onward and in the first condition-specific round.

Editorial history (pre-freeze)